While monoclonal antibodies (mAbs) have historically been a dominant force in the biopharmaceutical industry, over half of today’s global biologics pipeline includes a diverse range of recombinant proteins, new molecular formats, and bioconjugates. Moving forward, the global presence of these therapies is expected to grow at a rate two times faster than standard antibodies. This is due to their ability to be more precisely targeted and more potent, and potentially open up access to new therapeutic targets and biological mechanisms previously not accessible with mAbs. Nevertheless, realizing the potential of these next-generation molecules means finding appropriate expression technologies and development processes that can facilitate their path to market.
At Lonza, we have more than 35 years of experience in developing and manufacturing novel molecular formats, with 40% of the large molecules our teams support falling in this array of modalities from preclinical to commercial-stage development. Download this article in full to learn more about Lonza's mammalian and microbial expression technologies, which offer commercially viable systems that cover the diversity of complex proteins and are suitable for large-scale development. The combinatorial screening uses a broad range of genetic elements that mitigate the lack of predictability for both quantity and quality of your target protein. This, combined with extensive experience in establishing customized product-specific assay methods that aid in cell line decision, gives you the tools you need to be successful in a biopharmaceutical landscape that presents both new challenges as well as exciting opportunities.